Editorial: rapid disease progression in hepatitis delta-can we turn the tide?
- PMID: 31850558
- DOI: 10.1111/apt.15549
Editorial: rapid disease progression in hepatitis delta-can we turn the tide?
Comment on
-
Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia.Aliment Pharmacol Ther. 2020 Jan;51(1):158-166. doi: 10.1111/apt.15521. Epub 2019 Nov 13. Aliment Pharmacol Ther. 2020. PMID: 31721254
References
REFERENCES
-
- Palom A, Rodríguez-Tajes S, Navascués CA, et al. Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. Aliment Pharmacol Ther. 2020;51:158-166.
-
- Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
-
- El Bouzidi K, Elamin W, Kranzer K, et al. Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. J Clin Virol. 2015;66:33-37.
-
- Manesis EK, Vourli G, Dalekos G, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59:949-956.
-
- Arends P, Sonneveld MJ, Zoutendijk R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64:1289-1295.